Crataegus - Lichtwer Pharma

Drug Profile

Crataegus - Lichtwer Pharma

Alternative Names: LI 132

Latest Information Update: 09 Dec 1998

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Unknown
  • Developer Lichtwer Pharma
  • Class Cardiac glycosides; Cardiotonics; Heart failure therapies; Phytotherapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Heart failure

Most Recent Events

  • 09 Dec 1998 No-Development-Reported for Heart failure in Germany (PO)
  • 09 Oct 1996 Two studies have been added to the heart failure therapeutic trials and side effects sections ,
  • 30 Jan 1996 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top